Mark Lesselroth, president and CEO of BioPortUSA was recently asked to join the Advisory Board of PeriVision, a Swiss MedTech start-up focused on the Ophthalmic market. Patrick kessel, CEO of PeriVision said “having Mark join our team is an invaluable resource. PeriVision visual field testing software is running on calibrated Virtual Reality headsets. PeriVision’s patented machine learning algorithm cut down examination times to have more reliable results. The technology is being clinically tested and supported by key opinion leaders in ophthalmology.
Not only does he understand the American healthcare landscape but as someone who is living with Glaucoma, he can appreciate what we are doing and how it can help make a difference.” PeriVision is focused on developing the next generation of Visual Field technology using Artificial Intelligence combined with virtual reality goggles. “I am thrilled to be asked to join the board of PeriVision as I think their technology will revolutionize how patients are seen by Ophthalmologist and enable them to spend more time talking with the patient during an office visit” said Mark Lesselroth.
PeriVision’s goal is to help prevent blindness caused by glaucoma. Worldwide roughly 80 million people are affected by this incurable eye disease. Early detection and continuous monitoring is key to prevent people from getting blind.